Advertisement

BioDrugs

, Volume 23, Issue 1, pp 53–61 | Cite as

Ustekinumab

  • Juliane Weber
  • Susan J. Keam
Adis Drug Profile

Abstract

▴ Ustekinumab is a fully human monoclonal antibody that binds with high specificity and affinity to the cytokines interleukin (IL)-12 and IL-23, thereby suppressing IL-12- and IL-23-mediated inflammation associated with psoriasis.

▴ In two large, phase III trials in patients with moderate to severe plaque psoriasis, significantly more subcutaneous ustekinumab 45 or 90 mg recipients (administered as two injections 4 weeks apart) than placebo recipients achieved a 75% improvement on the Psoriasis Area and Severity Index (PASI 75) score at 12 weeks.

▴ Other efficacy measures, including the physician’s global assessment of clinical response at week 12, also favored ustekinumab over placebo. Psoriatic symptom control was maintained during ustekinumab maintenance therapy (administered once every 12 weeks) for up to 76 weeks.

▴ In a phase II trial in patients with active plaque psoriasis and psoriatic arthritis, signs and symptoms of arthritis and psoriatic symptom control were improved to a greater extent with ustekinumab than with placebo at 12 weeks, based on the proportion of patients achieving a 20% improvement in American College of Rheumatology response criteria (arthritis) or PASI 75 (skin symptoms).

▴ Health-related quality of life, assessed using the Dermatology Life Quality Index and the Health Assessment Questionnaire disability index, was improved to a significantly greater extent with ustekinumab than with placebo at week 12.

▴ Subcutaneous ustekinumab was generally well tolerated in clinical trials, with most treatment-emergent adverse events being of mild severity.

Keywords

Psoriasis Psoriatic Arthritis Plaque Psoriasis Ustekinumab Dermatology Life Quality Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments and Disclosure

The manuscript was reviewed by K. Reich, Dermatologikum Hamburg, Hamburg, Germany; W. Sterry, Department of Dermatology and Allergy, University Hospital Charite, Berlin, Germany.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

References

  1. 1.
    Griffiths CEM, Iaccarino L, Naldi L, et al. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol 2006 Jan 28; 24(1 Suppl. 40): S72–8PubMedGoogle Scholar
  2. 2.
    Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 May; 58(5): 826–50PubMedCrossRefGoogle Scholar
  3. 3.
    Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 Sep; 153(3): 486–97PubMedCrossRefGoogle Scholar
  4. 4.
    Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008 May; 58(5): 851–64PubMedCrossRefGoogle Scholar
  5. 5.
    Boker A, Kimball AB, Rolz-Cruz G. Biologicals in the treatment of psoriasis. Curr Opin Invest Drug 2007; 8(11): 939–46Google Scholar
  6. 6.
    Bartlett BL, Tyring SK. Ustekinumab for chronic plaque psoriasis. Lancet 2008 May 17; 371(9625): 1639–40PubMedCrossRefGoogle Scholar
  7. 7.
    Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007 Dec; 57(6): 1059–68PubMedCrossRefGoogle Scholar
  8. 8.
    Reddy M, Davis C, Wong J, et al. Modulation of CLA, IL-12R, CD40L, and IL-2Ra expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol 2007 May; 247(1): 1–11PubMedCrossRefGoogle Scholar
  9. 9.
    Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) [published erratum appears in Lancet 2008 May 17; 371 (9625): 1838]. Lancet 2008 May 17; 371(9625): 1665–74PubMedCrossRefGoogle Scholar
  10. 10.
    Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med 2007 Feb; 13(2): 139–45PubMedCrossRefGoogle Scholar
  11. 11.
    Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008 Feb; 144(2): 200–7PubMedCrossRefGoogle Scholar
  12. 12.
    Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007 Feb; 80(2): 273–90PubMedCrossRefGoogle Scholar
  13. 13.
    Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004 Dec; 123(6): 1037–44PubMedCrossRefGoogle Scholar
  14. 14.
    Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006 Oct 1; 177(7): 4917–26PubMedGoogle Scholar
  15. 15.
    Gottlieb AB, Cooper KD, McCormick TS, et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 2007 May; 23(5): 1081–92PubMedCrossRefGoogle Scholar
  16. 16.
    Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008 May 17; 371(9625): 1675–84PubMedCrossRefGoogle Scholar
  17. 17.
    Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2009 Feb; 49(2): 162–75PubMedCrossRefGoogle Scholar
  18. 18.
    European Medicines Agency. Stelara European public assessment report [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/stelara/stelara.htm [Accessed 2009 Feb 13]
  19. 19.
    US FDA. Briefing document: ustekinumab [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4361b1-01-FDA%20.pdf [Accessed 2008 Aug 28]
  20. 20.
    Griffiths CEM, Strober B, van der Kerkhof PCM, et al. A phase 3, multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis [abstract no. FP 1336 plus poster]. 17th Congress of the European Academy of Dermatology and Venereology; 2008 Sep 17–21; ParisGoogle Scholar
  21. 21.
    Reich K, Lebwohl M, Schenkel B, et al. Ustekinumab improves work productivity and decreases workdays missed due to psoriasis in patients with moderate to severe psoriasis [abstract no. PSS44]. Value Health 2008 May 30; 11(3): A298CrossRefGoogle Scholar
  22. 22.
    Lebwohl M, Schenkel B, Han C, et al. Ustekinumab significantly improves heath-related quality of life in patients with moderate to severe psoriasis [abstract no. FP 1362 plus poster]. 17th Congress of the European Academy of Dermatology and Venereology; 2008 Sep 17–21; ParisGoogle Scholar
  23. 23.
    Reich K, Schenkel B, Han C, et al. Ustekinumab reduces work limitations, increases work productivity and decreases workdays missed due to psoriasis in patients with moderate to severe psoriasis [abstract no. FP 1402 plus poster]. 17th Congress of the European Academy of Dermatology and Venereology; 2008 Sep 17–21; ParisGoogle Scholar
  24. 24.
    Papp K, Kaufmann R, Toth DP, et al. Comparable efficacy and safety of ustekinumab in moderate to severe psoriasis patients treated with systemic therapies and treatment naive patients [abstract no. FP 1388 plus poster]. 17th Congress of the European Academy of Dermatology and Venereology; 2008 Sep 17–21; ParisGoogle Scholar
  25. 25.
    Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/ 23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009 Feb 21; 373(9664): 633–40PubMedCrossRefGoogle Scholar
  26. 26.
    Johnson & Johnson. FDA issues complete response letter to Centocor for ustekinumab biologic license application [media release]. 2008 Dec 19 [online]. Available from URL: http://www.jnj.com/connect/news/all/20081219_093000 [Accessed 2008 Dec 23]

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, NorthShoreNew Zealand
  2. 2.Wolters Kluwer HealthPhiladelphiaUSA

Personalised recommendations